Anti-VEGF therapy is now an additional therapeutic strategy to surgery, chemotherapy and radiotherapy, and recent trials of antibodies to VEGF as adjuvant therapy have shown significant clinical benefit in colorectal cancer (Hurwitz et al, 2004), renal carcinoma, non small cell lung, ovarian and other cancers. This evidence concerns the gene VEGFA and renal carcinoma.